At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
In Brief
A Phase 2 clinical trial evaluating Cabozantinib and Pembrolizumab for Metastatic Head and Neck Carcinoma and 23 related conditions. Active but no longer recruiting, targeting 36 participants across 2 sites.
Detailed Summary
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the pathways needed for cell growth. Giving pembrolizumab and cabozantinib may improve the chances of tumor response in patients with head and neck squamous cell cancer.
Study Details
Timeline
Interventions
Given PO
Given IV